Neumarker

AI-empowered Brain Biomarker for Precision Neuromedicine 

Our mission is to develop reliable, actionable, and objective biomarkers that empower mental health clinicians, support CNS drug developers, and bring hope to CNS disease patients and their families.

Central nervous system (CNS) diseases, such as Alzheimer’s disease, depression, anxiety, bipolar disorder, schizophrenia, epilepsy, migraines, and addiction, affect nearly every family worldwide, contributing to trillions of dollars in healthcare costs each year. Treatments for CNS diseases are often ineffective, relying on a trial-and-error approach that prolongs treatment, increases patient distress, and further elevates healthcare expenses. CNS drug development programs also face significant obstacles, including low success rates, lengthy development timelines, and strong placebo effect. By harnessing the power of AI, we can now decode the complex functions of the human brain, uncovering key biomarkers that reveal both pathological conditions and responses to interventions.